Evidence map›Paper›PMID 42741713›Full record

ArticleInfection and drug resistance2026

Ceftolozane/Tazobactam Susceptibility in ESBL-Producing Enterobacterales: Insights from the SMART Program 2020-2022 in China.

Yanfei Wang, Yuke Zhang, Jingjing Quan, Ying Fu, Zhihui Zhou, Jiaqi Xia, Yunsong Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yanfei Wang *Department of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
Yuke Zhang *Department of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
Jingjing QuanDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
Ying FuDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
Zhihui ZhouDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.
Jiaqi XiaValue & Implementation, MSD China, Shanghai, 200030, People's Republic of China.
Yunsong YuDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Surveillance data on ceftolozane/tazobactam (C/T) activity against extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) in China remains limited. This study summarized species- and source-specific C/T susceptibility patterns using isolates collected through the Study for Monitoring Antimicrobial Resistance Trends (SMART) China program (2020-2022). Methods: Non-duplicate Enterobacterales isolates from bloodstream, intra-abdominal, respiratory, and urinary tract infections (BSI, IAI, RTI, UTI) were collected in 18 tertiary hospitals. Minimum inhibitory concentrations (MICs) were determined by broth microdilution and interpreted using CLSI M100 2025. ESBL-E were defined as ceftriaxone-nonsusceptible (i.e, intermediate or resistant) and carbapenem-susceptible Enterobacterales (CSE), with species-specific adjustments for Results: All Enterobacterales isolates meeting inclusion criteria were analyzed; isolation rate is reported by species for the seven most prevalent, which together comprised 93.5% of isolates; the remaining genera contributed to the aggregate totals. Overall susceptibility of Enterobacterales to C/T was high. Among CSE, susceptibility was 92.2%, with 83.1% in ESBL‑E. By infection site, C/T susceptibility among ESBL‑E was 88.3% in UTI, 85.3% in BSI, 79.9% in RTI, and 77.4% in IAI. Susceptibility was highest in ESBL- Conclusion: C/T susceptibility among ESBL-E was high in

Indexed as

ceftolozane/tazobactamdrug resistanceESBL‑producing EnterobacteralesSMART

Identifiers

PMID42741713
PMCPMC13573848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.